Condition
Left Ventricular Outflow Tract Obstruction
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Mavacamten
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 2 (1)
Trial Status
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07120776Not ApplicableRecruiting
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
NCT02842242Phase 2Completed
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Showing all 2 trials
Research Network
Common Treatments
- Mavacamten1
- Myk4611
Active Sponsors
- University of Manchester1
- MyoKardia, Inc.1
Top Investigators
MyoKardia, Inc.
University of Manchester
Related Conditions
- Hypertrophic Obstructive Cardiomyopathy Hocm1
- Myocardial Ischaemia1
- Cardiomyopathy Hypertrophic Obstructive1